"Understanding biologic therapy trajectories in Medicaid is important, given its distinct formulary restrictions and patient demographics," they concluded. "Interventions must not only address access ...

In patients with psoriasis, biologics may reduce ocular surface and corneal inflammation — especially dry eye, conjunctivitis ...

The results of 2 recent clinical trials combining the GLP-1 drug and the biologic reinforce the benefits of treating obesity ...

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the landmark TOGETHER-PsO open-label Phase 3b ...

Conclusions: With the development of recombinant DNA techniques, it has become possible to develop new biologic therapies that can be designed to specifically alter physiological responses. These new ...

Interleukin-23 inhibitors, prior treatment history, and Psoriasis Area and Severity Index scores may be predictive of time to disease relapse among patients with psoriasis who achieved clinical ...

Patients with psoriasis who have active cancer or who have had cancer within 5 years can safely use biologics.

Combination ixekizumab plus tirzepatide outperformed ixekizumab monotherapy for the treatment of both psoriasis and ...

Higher BMI, BMR, BSA, and weight correlate with more severe psoriasis and reduced treatment efficacy, particularly with biologic therapies. Personalized dosing strategies may be necessary for biologic ...

Please provide your email address to receive an email when new articles are posted on . The majority of patients and clinicians agreed with the use of as-needed biologic therapy for psoriasis.

For patients with plaque psoriasis who initiated treatment with a first-line biologic, the average treatment cost more than doubled from 2007 to 2021 as more patients started newer IL-17 and IL-23 ...

A 46-year-old man presents for his first dermatology consultation for worsening symptoms of plaque psoriasis and recent-onset joint pain. He reports “painful aching” and swelling of his finger joints, ...